Novanta Inc. has acquired Riverpoint Medical for $1.4 billion. The transaction sees Novanta Inc. take ownership of Riverpoint Medical, a specialty device manufacturer known for its next-generation medical devices serving both veterinary and human healthcare markets. This acquisition marks a significant expansion for Novanta Inc. within the medical technology sector.
Riverpoint Medical, based in Portland, has established itself as a key innovator in medical device manufacturing. The company is recognized as one of the few suture manufacturers in the United States, specializing in synthetic absorbable and orthopedic suture materials. Its HS Fiber® UHMWPE suture line is particularly noted for sports medicine applications. Beyond sutures, Riverpoint Medical also produces cutting-edge LED surgical headlights and a comprehensive range of oncology needle products, demonstrating a broad commitment to improving surgical practices through innovation.
This strategic acquisition is expected to enhance Novanta Inc.'s portfolio by integrating Riverpoint Medical's specialized manufacturing capabilities and innovative product lines. The addition of Riverpoint Medical's expertise in high-performance sutures and other medical devices is anticipated to create synergies, allowing Novanta Inc. to expand its offerings and strengthen its position in critical areas of the medical device market. The move aligns with a strategy to leverage Riverpoint Medical's focus on rapid market response and continuous improvement in surgical technology.
Looking ahead, the combined entity is poised to deliver an expanded suite of advanced medical solutions. This integration is expected to drive further innovation in surgical devices and materials, ultimately benefiting healthcare providers and patients across veterinary and human medicine by offering a more comprehensive and technologically advanced product range.